Overview

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
0
Participant gender:
All
Summary
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This is a Phase 1/2 open-label study to evaluate the safety of autologous genetically engineered TC-110 T cells in patients with aggressive NHL (DLBCL, PMBCL, TFL), high-risk indolent NHL (including MCL), or adult ALL.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
TCR2 Therapeutics
Treatments:
Cyclophosphamide
Fludarabine
Criteria
Inclusion Criteria:

- Patient is > 18 years of age at the time the Informed Consent is signed

- Patient has agreed to abide by all protocol-required procedures, including
study-related assessments, and management by the treating institution for the duration
of the study and LTFU

- Histologically confirmed NHL or ALL

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Patient must have adequate organ function as indicated by the laboratory values in the
clinical protocol

- Patient must be fit for leukapheresis and have adequate venous access for cell
collection

- Patient must have evidence of CD19 expression

- Prior CD19-directed CAR T therapy is allowed